| Description | Elvucitabine, a reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection and HIV infection. |
| Synonyms | ACH126443, TY-202, L-D-4FC, beta-L-Fd-4C, ACH 126443, ACH-126443 |
| molecular weight | 227.19 |
| Molecular formula | C9H10FN3O3 |
| CAS | 181785-84-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Colucci P, Pottage JC, Robison H, Turgeon J, Ducharme MP. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother. 2009 Feb;53(2):646-50. doi: 10.1128/AAC.00905-08. PubMed PMID: 19015353; PubMed Central PMCID: PMC2630647. 2. Colucci P, Pottage JC, Robison H, Turgeon J, Schürmann D, Hoepelman IM, Ducharme MP. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob Agents Chemother. 2009 Feb;53(2):662-9. doi: 10.1128/AAC.00907-08. PubMed PMID: 19015343; PubMed Central PMCID: PMC2630663. 3. Elvucitabine data released at CROI. AIDS Patient Care STDS. 2010 Mar;24(3):198. PubMed PMID: 20235383. 4. Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51(6):2130-5. PubMed PMID: 17403996; PubMed Central PMCID: PMC1891415. |